FLGT
Fulgent Genetics Inc

5,758
Loading...
Loading...
News
all
press releases
Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +130.43% and +7.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·7mo ago
News Placeholder
Fulgent Reports Third Quarter 2024 Financial Results
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Business Wire·10mo ago
News Placeholder
Uncovering Potential: Fulgent Genetics's Earnings Preview
read more...
Benzinga·10mo ago
News Placeholder
Fulgent to Participate in Upcoming Conferences
Fulgent Genetics, Inc. (NASDAQ:FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·11mo ago
News Placeholder
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Business Wire·11mo ago
News Placeholder
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·11mo ago
News Placeholder
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced...
Business Wire·1y ago
News Placeholder
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical...
Business Wire·1y ago
News Placeholder
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical...
Business Wire·1y ago

Latest FLGT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.